Daniel Calabrese, MD
Assistant Professor
Medicine
School of Medicine

415-476-0735

Dr. Calabrese is an Assistant Professor of Medicine at UCSF and a Staff Physician at the San Francisco VA Medical Center. He received his undergraduate degree from Washington University in St. Louis and completed his MD at Case Western Reserve University School of Medicine.

Show full bio (110 words) Hide full bio

He serves as an attending physician in the intensive care unit, pulmonary consult service and outpatient pulmonary clinic at the SF VAMC. He is also an attending physician for the Advanced Lung Disease Service at UCSF Parnassus where he evaluates patients in the lung transplant clinics. He is active in the International Society for Heart and Lung Transplantation.

His research focuses on the mechanisms for innate immune inflammation in lung transplant outcomes. This research uses mouse models of human lung disease and human tissue samples to understand primary graft dysfunction, antibody-mediated rejection and chronic lung allograft dysfunction. The goal of this work is to improve outcomes following lung transplantation.

Awards

Show all (2) Hide

  • Young Physician-Scientist Award, ASCI, 2023
  • Research and Immunology Professional Community Award for Excellence, ISHLT, 2022-2023

Education & Training

Show all (5) Hide

  • Diversity, Equity, and Inclusion Champion Training University of California San Francisco 2020
  • Fellowship Pulmonary and Critical Care University of California San Francisco 07/2018
  • Residency Internal Medicine University of Washington 07/2014
  • MD Case Western Reserve University 05/2011
  • BS Anthropology, Biology Washington University in St. Louis 05/2006

Interests

Show all (9) Hide

  • advanced lung disease
  • antibody-mediated rejection
  • cystic fibrosis
  • innate immune system
  • dectin-1
  • natural killer cells
  • lung transplantation
  • cytomegalovirus
  • chronic lung allograft dysfunction

Websites

Show all (3) Hide

Grants and Projects

Show all (5) Hide

  • NK cells in pulmonary ischemia-reperfusion injury, VA BLRD, 2021-2026
  • Targeting airway hypoxia pathways in Cystic Fibrosis, Cystic Fibrosis Foundation, 2022-2024
  • NKG2D stress molecules in lung allograft dysfunction, American Society of Transplantation, 2022-2024
  • Natural killer cells in primary graft dysfunction, Cystic Fibrosis Foundation, 2019-2022
  • Targeting Antibody-Dependent NK Cell-mediated Rejection Pathways in Lung Allograft Recipients, ISHLT, 2019-2021

Publications (44)

Top publication keywords:
Graft RejectionFrailtyKiller Cells, NaturalLungTacrolimusPrimary Graft DysfunctionBronchoalveolar LavageAllograftsNK Cell Lectin-Like Receptor Subfamily KAcute Lung InjuryLung InjuryLung TransplantationAntibodiesNK Cell Lectin-Like Receptor Subfamily CReperfusion Injury

Show all (39 more) Hide